Andere talen Vaccinex, Inc.

Aandelen

VCNX

US9186403013

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,49 ^USD	+5,04%		+6,39%	-30,27%

06/06	Vaccinex meldt voltooiing laatste patiëntenbezoek in gerandomiseerde SIGNAL-AD fase 1b/2-studie naar pepinemab-behandeling voor de ziekte van Alzheimer	CI
15/05	Vaccinex, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's disease	07/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease	06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer?s Disease	06/06
Vaccinex : ASCO Conference Presentation	01/06
Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	16/05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update	16/05
Vaccinex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
VACCINEXPAR : 12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation	26/04
Vaccinex, Inc. announced that it has received $1.75 million in funding	12/04
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	02/04
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	29/03
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	28/03
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	27/03
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	27/03
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	27/03
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	04/03
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	04/03
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	21/02
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vaccinex, Inc.

Aandelen

VCNX

US9186403013

Andere talen

Filters